Tesofensine

DB06156InvestigationalSmall molecule

Investigated for use/treatment in alzheimer's disease, parkinson's disease, and obesity.

Mechanism: Tesofensine is a Serotonin-norepinephrine-dopamine-reuptake-inhibitor (SNDRI). SNDRIs are a class of psychoactive antidepressants. They act upon neurotransmitters in the brain, namely, serotonin, norepinephrine and dopamine. These three biogenic monoamines are associated with depression and increasing the availability in the brain is one method used to treat the condition.
Curator reviewed
Primary indication: Investigated for use/treatment in alzheimer's disease, parkinson's disease, and obesity.Curator reviewed
Formula / weight: C₁₇H₂₃Cl₂NO · 328.28 g/mol (avg)
Code names: NS-2330

Resolves to

Compound

Structure

InChIKeyVCVWXKKWDOJNIT-ZOMKSWQUSA-NSMILESCCOC[C@H]1[C@H]2CC[C@@H](C[C@@H]1C1=CC(Cl)=C(Cl)C=C1)N2C

Targets

What you can answer from here — as of August 30, 2026

4Protein targetsEach mapped to UniProt, with action and pharmacological action

Listed above

10Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with Tesofensine, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.